Sungpil Han1, Yo-Han Kim1, Hee Youn Choi1, Mi-Jo Kim1, Wan Joo Kim1, Hyunjung Park2, Kyun-Seop Bae1, Hyeong-Seok Lim3. 1. Department of Clinical Pharmacology and Therapeutics, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea. 2. Clinical Pharmacology Laboratory, Asan Institute for Life Sciences Building, ASAN Medical Center, Seoul, Republic of Korea. 3. Department of Clinical Pharmacology and Therapeutics, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea. mdhslim@gmail.com.
Abstract
PURPOSE:CTB-001, a recently developed generic version of bivalirudin, an FDA-approved anticoagulant used for prophylaxis and treatment of cardiovascular diseases, has shown good efficacy and safety in clinical trials. We characterized the pharmacokinetics (PK) and pharmacodynamics (PD) of CTB-001 by modeling and simulation analysis. METHODS: PK/PD data were collected from a randomized, double-blind, placebo-controlled, single-dose, dose-escalation phase 1 study conducted in 24 healthy Korean male subjects. PK/PD analysis was conducted sequentially by nonlinear mixed-effects modeling implemented in NONMEM®. Monte-Carlo simulations were conducted for PK, activated partial thromboplastin time (aPTT), prothrombin time (PT), and thrombin time (TT). RESULTS: The CTB-101 PK was best described by a three-compartment linear model with a saturable binding peripheral compartment. All PD endpoints showed dose-response relationship, and their changes over time paralleled those of CTB-101 concentrations. A simple maximum effect model best described the aPTT, PT in INR, PT in seconds, and TT, whereas an inhibitory simple maximum effect model best described PT in percentages. The maximum duration of effect of CTB-001 on aPTT prolongation was 52.1 s. CONCLUSIONS: The modeling and simulation analysis well-characterized the PK and PD of CTB-001 in healthy Koreans, which will be valuable for identifying optimal dosing regimens of CBT-001.
RCT Entities:
PURPOSE:CTB-001, a recently developed generic version of bivalirudin, an FDA-approved anticoagulant used for prophylaxis and treatment of cardiovascular diseases, has shown good efficacy and safety in clinical trials. We characterized the pharmacokinetics (PK) and pharmacodynamics (PD) of CTB-001 by modeling and simulation analysis. METHODS: PK/PD data were collected from a randomized, double-blind, placebo-controlled, single-dose, dose-escalation phase 1 study conducted in 24 healthy Korean male subjects. PK/PD analysis was conducted sequentially by nonlinear mixed-effects modeling implemented in NONMEM®. Monte-Carlo simulations were conducted for PK, activated partial thromboplastin time (aPTT), prothrombin time (PT), and thrombin time (TT). RESULTS: The CTB-101 PK was best described by a three-compartment linear model with a saturable binding peripheral compartment. All PD endpoints showed dose-response relationship, and their changes over time paralleled those of CTB-101 concentrations. A simple maximum effect model best described the aPTT, PT in INR, PT in seconds, and TT, whereas an inhibitory simple maximum effect model best described PT in percentages. The maximum duration of effect of CTB-001 on aPTT prolongation was 52.1 s. CONCLUSIONS: The modeling and simulation analysis well-characterized the PK and PD of CTB-001 in healthy Koreans, which will be valuable for identifying optimal dosing regimens of CBT-001.
Authors: David E Allie; Mitchell D Lirtzman; Charles H Wyatt; V Antoine Keller; Mohamed H Khan; Muhammad A Khan; Peter S Fail; Chris J Hebert; Sonja D Ellis; Elena Mitran; Gary Chaisson; Samuel Stagg; Adam A Allie; Craig M Walker Journal: J Invasive Cardiol Date: 2003-06 Impact factor: 2.022
Authors: Freek W A Verheugt; Steven R Steinhubl; Martial Hamon; Harald Darius; Philippe Gabriel Steg; Marco Valgimigli; Steven P Marso; Sunil V Rao; Anthony H Gershlick; A Michael Lincoff; Roxana Mehran; Gregg W Stone Journal: JACC Cardiovasc Interv Date: 2011-02 Impact factor: 11.195
Authors: John W Eikelboom; Shamir R Mehta; Sonia S Anand; Changchun Xie; Keith A A Fox; Salim Yusuf Journal: Circulation Date: 2006-08-14 Impact factor: 29.690